X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8) 8
index medicus (8) 8
middle aged (8) 8
female (7) 7
oncology (7) 7
aged (6) 6
clinical trials (6) 6
male (6) 6
adult (5) 5
hematology, oncology and palliative medicine (5) 5
metastasis (5) 5
studies (5) 5
chemotherapy (4) 4
disease-free survival (4) 4
double-blind method (4) 4
melanoma (4) 4
melanoma - drug therapy (4) 4
survival (4) 4
young adult (4) 4
adolescent (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer (3) 3
care and treatment (3) 3
ipilimumab (3) 3
patients (3) 3
sarcoma (3) 3
therapy (3) 3
treatment outcome (3) 3
adjuvants, immunologic (2) 2
aged, 80 and over (2) 2
antibodies, monoclonal (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - adverse effects (2) 2
cancer therapies (2) 2
dacarbazine (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
drug dosages (2) 2
expression (2) 2
follow-up studies (2) 2
intention to treat analysis (2) 2
intravenous administration (2) 2
liposarcoma (2) 2
lymphatic system (2) 2
malignancy (2) 2
medical colleges (2) 2
medicine, general & internal (2) 2
melanoma - pathology (2) 2
melanoma - surgery (2) 2
motivation (2) 2
multicenter (2) 2
node-positive melanoma (2) 2
product development (2) 2
quality of life (2) 2
radiation therapy (2) 2
scores (2) 2
standards (2) 2
surgery (2) 2
survival rate (2) 2
tumors (2) 2
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
abdominal wall (1) 1
abridged index medicus (1) 1
adjuvant treatment (1) 1
adjuvants, immunologic - administration & dosage (1) 1
adjuvants, immunologic - therapeutic use (1) 1
adverse events (1) 1
aggressive behavior (1) 1
akt (1) 1
alanine (1) 1
alanine transaminase (1) 1
alanine transaminase - blood (1) 1
anemia (1) 1
anemia - chemically induced (1) 1
anthracyclines (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antitumor agents (1) 1
article (1) 1
back (1) 1
benign (1) 1
biochemistry & molecular biology (1) 1
biocompatibility (1) 1
biomedical materials (1) 1
biopsy (1) 1
bone (1) 1
bone dysplasia (1) 1
bone neoplasms - diagnosis (1) 1
bone neoplasms - drug therapy (1) 1
bone neoplasms - enzymology (1) 1
bone neoplasms - pathology (1) 1
cancer clinical-trials (1) 1
cancer-immunotherapy (1) 1
capecitabine (1) 1
cd8 (1) 1
cd8 t cells (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 812 - 822
Summary Background Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CRITERIA | THERAPY | RECIST | CLINICAL-TRIAL | HIGH-GRADE | ONCOLOGY | DOSE ADJUVANT CHEMOTHERAPY | EXTREMITIES | TUMOR RESPONSE ASSESSMENT | IFOSFAMIDE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Trabectedin | Sarcoma - therapy | Young Adult | Neurilemmoma - therapy | Dioxoles - administration & dosage | Back | Adult | Neutropenia - chemically induced | Child | Extremities | Soft Tissue Neoplasms - therapy | Dacarbazine - administration & dosage | Thoracic Wall | Sarcoma, Synovial - therapy | Deoxycytidine - administration & dosage | Risk Factors | Docetaxel | Anemia - chemically induced | Etoposide - administration & dosage | Tetrahydroisoquinolines - administration & dosage | Thrombocytopenia - chemically induced | Abdominal Wall | Sarcoma - pathology | Leiomyosarcoma - therapy | Disease-Free Survival | Taxoids - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - methods | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Deoxycytidine - analogs & derivatives | Liposarcoma, Myxoid - therapy | Care and treatment | Anthracyclines | Sarcoma | Adjuvant treatment | Clinical trials | Product development | Standards | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 522 - 530
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 98 - 107
Journal Article
Journal Article
OncoImmunology, ISSN 2162-4011, 05/2016, Volume 5, Issue 5, p. e1114203
The identification of activation pathways linked to antitumor T-cell polyfunctionality in long surviving patients is of great relevance in the new era of... 
Human melanoma | Dacarbazine | Chemoimmunotherapy | Polyfunctional | CD8 | AKT | T cells | ICOS | Melan-A | CTLA-4 BLOCKADE | chemo-immunotherapy | VIRUS | RECEPTOR | polyfunctional | IMMUNOLOGY | EFFECTOR | IN-VITRO | INHIBITION | MEMORY | ONCOLOGY | PATHWAY | CD8(+) T cells | human melanoma | PD-1 | dacarbazine | LYMPHOCYTES
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.